News & Updates
Showing Pharmacy articles
Showing
Updated long-term data AUGMENT R2 efficacy for R/R iNHL
In the longer-term follow-up of the phase III AUGMENT trial, the lenalidomide-rituximab (R2) combination trumped the rituximab-placebo regimen (control) for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
Updated long-term data AUGMENT R2 efficacy for R/R iNHL
22 Dec 2022
No excess pancreatic cancer risk with dihydropyridine calcium channel blockers, study says
Exposure to dihydropyridine calcium channel blockers does not appear to put patients at increased risk of developing pancreatic cancer as compared with thiazide diuretics, as shown in a large study.
No excess pancreatic cancer risk with dihydropyridine calcium channel blockers, study says
22 Dec 2022
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
Rapidly maximizing medications in patients discharged from hospital following acute heart failure (AHF) reduced the risk of hospital readmission or death at 180 days, according to results of the STRONG-HF* trial presented at AHA 2022.
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
21 Dec 2022
EMERALD updates highlight therapeutic potential of elacestrant for ER+/HER2– mBC
In the updated analysis of the phase III EMERALD trial, the next-generation oral SERD* elacestrant continued to show favourable signals for the treatment of ER+/HER2– metastatic breast cancer (mBC).
EMERALD updates highlight therapeutic potential of elacestrant for ER+/HER2– mBC
20 Dec 2022
Metformin may reduce COVID-19 severity in prediabetes, PCOS
Among patients with prediabetes or polycystic ovary syndrome (PCOS), the use of metformin appears to be associated with lower incidence of severe COVID-19, according to a study.